Fifth Third Bancorp
PTGX icon

Fifth Third Bancorp’s Protagonist Therapeutics PTGX Stock Holding History

Fifth Third Bancorp’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.61M Sell
13,112
-90
-0.7% -$9.4K ﹤0.01% 1395
2026
Q1 		$1.39M Buy
13,202
+12,875
+3,937% +$1.14M ﹤0.01% 1423
2025
Q4 		$28.6K Buy
327
+20
+7% +$1.64K ﹤0.01% 1727
2025
Q3 		$20.4K Buy
307
+96
+45% +$5.46K ﹤0.01% 1880
2025
Q2 		$11.7K Sell
211
-71
-25% -$3.41K ﹤0.01% 1967
2025
Q1 		$13.6K Buy
282
+190
+207% +$7.96K ﹤0.01% 1888
2024
Q4 		$3.55K Sell
92
-11
-11% -$480 ﹤0.01% 2230
2024
Q3 		$4.63K Buy
+103
New +$4.16K ﹤0.01% 2204

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fifth Third Bancorp's PTGX Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Protagonist Therapeutics (PTGX) stake by 0.68% in Q2 2026, selling an estimated $9.4K and leaving 13,112 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1395.

Fifth Third Bancorp first reported a position in PTGX in Q3 2024 and has held it in 8 quarters since. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Fifth Third Bancorp held 13,112 shares of Protagonist Therapeutics worth $1.61M as of Q2 2026.
  • Fifth Third Bancorp sold 90 Protagonist Therapeutics shares in Q2 2026, an estimated $9.4K.
  • Protagonist Therapeutics made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #1395 holding.
  • Fifth Third Bancorp first reported a position in Protagonist Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.